Polymorphisms in CYP1A2,CYP2C9 and ABCB1 affect agomelatine pharmacokinetics

Abstract

Background:

Agomelatine is an agonist of the melatoninergic receptors used for the treatment of depression. Our aim was to evaluate the effect of genetic polymorphisms in metabolising enzymes and the P-glycoprotein transporter on agomelatine pharmacokinetics and pharmacodynamics.

Methods:

Twenty-eight healthy volunteers receiving a single 25 mg oral dose of agomelatine, were genotyped for nine polymorphisms in cytochrome P450 enzymes (CYP1A2, CYP2C9 and CYP2C19) and adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1), by real-time polymerase chain reaction . Agomelatine concentrations were measured by high performance liquid chromatography coupled to a tandem mass spectrometry detector.

Results:

We calculated a CYP1A2 activity score that was directly correlated with agomelatine pharmacokinetics. Individuals with a decreased enzyme activity (*1C carriers) had a lower clearance and accumulated higher concentrations of agomelatine. In contrast, individuals with a high CYP1A2 inducibility (*1F or *1B carriers) showed an extensive clearance and lower agomelatine concentrations. The apparently marked differences between races were due to the different CYP1A2 genotype distribution. CYP2C9 intermediate/poor metabolisers showed a higher area under the concentration-time curve and maximum concentration. ABCB1 G2677T/A polymorphism affected the time to reach maximum concentration, as subjects carrying A/A+A/T genotypes showed higher values. No association was found for CYP2C19 phenotype. Agomelatine did not produce any change in blood pressure, heart rate or QT interval.

Conclusions:

CYP1A2 polymorphisms affect agomelatine pharmacokinetics. CYP1A2 phenotype inferred from the genotyping of CYP1A2*1C, *1F and *1B alleles might be a potential predictor of agomelatine exposure. ABCB1 G2677T/A could affect agomelatine absorption, as subjects with A/A+A/T genotypes had lower agomelatine concentration and they take more time to reach the maximum concentration.

Keywords

Pharmacogenetics antidepressant agomelatine pharmacokinetics cytochrome P450

Get full access to this article

View all access options for this article.

References

1000 Genomes Project Consortium, Auton

Brooks

et al . (2015) A global reference for human genetic variation. Nature 526: 68–74.

Ambudkar

Dey

Hrycyna

et al . (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39: 361–398.

Agencia Española de Medicamentos y Productos Sanitarios (2018) label information for agomelatine. Madrid: AEMPS. Available at: https://cima.aemps.es/cima/pdfs/es/ft/83453/83453_ft.pdf (accessed 30 January 2018).

Bazett

(1997) An analysis of the time-relations of electrocardiograms. Ann Noninvasive Electrocardiol 2: 177–194.

Buoli

Grassi

Serati

et al . (2017) Agomelatine for the treatment of generalized anxiety disorder. Expert Opin Pharmacother 18: 1373–1379.

Caudle

Dunnenberger

Freimuth

et al . (2017) Standardizing terms for clinical pharmacogenetic test results: Consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med 19: 215–223.

de Bodinat

Guardiola-Lemaitre

Mocaër

et al . (2010) Agomelatine, the first melatonergic antidepressant: Discovery, characterization and development. Nat Rev Drug Discov 9: 628–642.

European Medicines Agency (2011) Guideline on Bioanalytical Method Validation. EMEA/CHMP/EWP/192217/2009. London: EMA. Available at: http://www.ema.europa.eu/docs/enGB/documentlibrary/Scientificguideline/2011/08/WC500109686.pdf (accessed 28 June 2018).

European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP) (2010) Guideline on the Investigation of Bioequivalence. London: EMA Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf (accessed 28 June 2018).

10.

Feise

(2002) Do multiple outcome measures require p-value adjustment? BMC Med Res Methodol 2: 8.

11.

Freiesleben

Furczyk

(2015) A systematic review of agomelatine-induced liver injury. J Mol Psychiatry 3: 4.

12.

Gottesman

Pastan

Ambudkar

(1996) P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 6: 610–617.

13.

Hardy-Weinberg equilibrium test for association (2018) Available at: http://ihg.gsf.de/cgi-bin/hw/hwa1.pl (accessed July 2018).

14.

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (2005) The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs E14. Geneva: ICH. Available at: http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/the-clinical-evaluation-of-qtqtc-interval-prolongation-and-proarrhythmic-potential-for-non-antiarrh.html (accessed 6 July 2018).

15.

Jeleń

Sałagacka

Żebrowska

et al . (2015) The influence of C3435T polymorphism of the ABCB1 gene on genetic susceptibility to depression and treatment response in polish population - preliminary report. Int J Med Sci 12: 974–979.

16.

Karch

Lasagna

(1977) Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther 21: 247–254.

17.

Kasper

Hajak

Wulff

et al . (2010) Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: A randomized, double-blind comparison with sertraline. J Clin Psychiatry 71: 109–120.

18.

Kennedy

Rizvi

(2010) Agomelatine in the treatment of major depressive disorder: Potential for clinical effectiveness. CNS Drugs 24: 479–499.

19.

Laux

Barthel

Hajak

et al . (2017) Pooled analysis of four non-interventional studies: Effectiveness and tolerability of the antidepressant agomelatine in daily practice. Adv Ther 34: 895–914.

20.

Laux

and the VIVALDI Study Group (2012) The antidepressant agomelatine in daily practice: Results of the non-interventional study VIVALDI. Pharmacopsychiatry 45: 284–291.

21.

Zheng

et al . (2017) Bioequivalence and pharmacokinetic profiles of agomelatine 25-mg tablets in healthy Chinese subjects: A four-way replicate crossover study demonstrating high intra- and inter-individual variations. Chem Pharm Bull (Tokyo) 65: 524–529.

22.

Nakajima

Yokoi

Mizutani

et al . (1999) Genetic polymorphism in the 5’-flanking region of human CYP1A2 gene: Effect on the CYP1A2 inducibility in humans. J Biochem (Tokyo) 125: 803–808.

23.

Pei

Wang

et al . (2014) Evaluation of the highly variable agomelatine pharmacokinetics in Chinese healthy subjects to support bioequivalence study. PLoS One 9: e109300.

24.

Perneger

(1998) What’s wrong with Bonferroni adjustments. BMJ 316: 1236–1238.

25.

Rothman

(1990) No adjustments are needed for multiple comparisons. Epidemiology 1: 43–46.

26.

Saiz-Rodríguez

Belmonte

Román

et al . (2018) Effect of ABCB1 C3435T polymorphism on pharmacokinetics of antipsychotics and antidepressants. Basic Clin Pharmacol Toxicol 123: 474–485.

27.

Savitz

Olshan

(1998) Describing data requires no adjustment for multiple comparisons: A reply from Savitz and Olshan. Am J Epidemiol 147: 813–814; discussion 815.

28.

Song

Jiang

et al . (2014) Effect of CYP1A2 polymorphism on the pharmacokinetics of agomelatine in Chinese healthy male volunteers. J Clin Pharm Ther 39: 204–209.

29.

Srinivasan

De Berardis

Shillcutt

et al . (2012) Role of melatonin in mood disorders and the antidepressant effects of agomelatine. Expert Opin Investig Drugs 21: 1503–1522.

30.

Stahl

(2014) Mechanism of action of agomelatine: A novel antidepressant exploiting synergy between monoaminergic and melatonergic properties. CNS Spectr 19: 207–212.

31.

The Pharmacogene Variation (PharmVar) Consortium (2018a) CYP2C9 Allele Nomenclature. Available at: https://www.pharmvar.org/gene/CYP2C9 (accessed 27 July 2018).

32.

The Pharmacogene Variation (PharmVar) Consortium (2018b) CYP2C19 Allele Nomenclature. Available at: https://www.pharmvar.org/gene/CYP2C19 (accessed 27 July 2018).

33.

Thompson

(1998) Invited commentary: Re: “Multiple comparisons and related issues in the interpretation of epidemiologic data.” Am J Epidemiol 147: 801–806.

34.

World Health Organization (2018) Depression and Other Common Mental Disorders. Geneva: WHO. Available at: http://www.who.int/mental_health/management/depression/prevalence_global_health_estimates/en/ (accessed 6 June 2018).